Priftin Tablet, Film Coated
NDC Package 0088-2102-24

11-digit billing NDC: 00088210224 · Billing unit: EA · 24 EA per package
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Priftin (rifapentine) tablets is pRIFTIN® (rifapentine) is indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. This formulation utilizes a tablet, film coated delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0088-2102 and is authorized under FDA application NDA021024.

Identification & Billing

NDC Package Code
0088-2102-24
Package Description
3 BLISTER PACK in 1 CARTON / 8 TABLET, FILM COATED in 1 BLISTER PACK (0088-2102-01)
Product Code
0088-2102
11-Digit Billing Format
00088210224
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
24 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Priftin
Non-Proprietary Name
Rifapentine
Substance Name
Rifapentine
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
RIFAPENTINE 150 mg/1
Pharmacologic Class
Usage Information
PRIFTIN® (rifapentine) is indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible [see Dosage and Administration (2.1) and Clinical Studies (14.1)].

Regulatory & Marketing

Labeler Name
Sanofi-aventis U.s. Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021024
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-08-2017
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0088-2102-24 identifies a specific commercial package of 3 blister pack in 1 carton / 8 tablet, film coated in 1 blister pack (0088-2102-01) of Priftin, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This tablet, film coated is formulated for oral use and contains rifapentine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on February 08, 2017. The current certification is valid through December 31, 2027.

How is this Sanofi-aventis U.s. Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00088210224. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 24 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0088-2102-24
11-Digit CMS (5-4-2)
00088-2102-24

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.